Breaking: DEA Reportedly Moves To Reschedule Cannabis, Stocks Rise Sharply On The News

The U.S. Drug Enforcement Administration will move to reclassify marijuana as a less dangerous drug, the Associated Press reported on Tuesday early afternoon, calling it a "historic shift to generations of American drug policy that could have wide ripple-effects across the country."

The DEA's proposal, which still must be reviewed by the White House Office of Management and Budget, says the outlet, would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than some of the nation's most dangerous drugs. However, it would not legalize marijuana outright for recreational use.

The agency's move, confirmed to the AP on Tuesday by five people familiar with the matter who spoke on the condition of anonymity to discuss the sensitive regulatory review, clears the last significant regulatory hurdle before the agency's biggest policy change in over 50 years can take effect.

Once OMB signs off, the DEA is expected to take public comment on the plan to move marijuana from its current classification as a Schedule I drug, which it occupies along such dangerous drugs as heroin and LSD.

Also Read: EXCLUSIVE: How Dreka Gates Transforms Cannabis Perceptions

Reclassification would move cannabis to Schedule III, following a recommendation from the Deptment of Health and Human Services to do this very thing. After the public-comment period, the agency would publish the final rule.

Cannabis stocks are up sharply with the news. The AdviserShares Pure U.S Cannabis ETF MSOS was up by 22.8%.

If you are interested in the financial outcomes of the cannabis industry, then you might be interested in attending Benzinga’s Cannabis Capital Conference in Chicago on Oct. 8-9. Network with key industry players, hear from the top operators, and close deals that will shape the future. Act now— spots are filling fast. Get your tickets here.

More Coverage And Reactions On Benzinga Cannabis

Now Read: Revenue Down, Margins Up: Lifeist’s Q1 Financial Results Show Focus On Premium Products Curbed Revenue Drop

Image generated using artificial intelligence via Midjourney.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsLegalTop StoriesDEA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.